+

US20080241188A1 - Turkey herpesvirus vectored recombinant containing avian influenza genes - Google Patents

Turkey herpesvirus vectored recombinant containing avian influenza genes Download PDF

Info

Publication number
US20080241188A1
US20080241188A1 US11/729,978 US72997807A US2008241188A1 US 20080241188 A1 US20080241188 A1 US 20080241188A1 US 72997807 A US72997807 A US 72997807A US 2008241188 A1 US2008241188 A1 US 2008241188A1
Authority
US
United States
Prior art keywords
recombinant
turkey herpesvirus
avian influenza
seq
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/729,978
Inventor
Motoyuki Esaki
Lauren Elizabeth Jensen
Kristi M. Dorsey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeon Corp
Original Assignee
Zeon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeon Corp filed Critical Zeon Corp
Priority to US11/729,978 priority Critical patent/US20080241188A1/en
Assigned to ZEON CORPORATION reassignment ZEON CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ESAKI, MOTOYUKI
Assigned to BIOMUNE COMPANY reassignment BIOMUNE COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DORSEY, KRISTI M., JENSEN, LAUREN ELIZABETH
Assigned to ZEON CORPORATION reassignment ZEON CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOMUNE CORPORATION
Assigned to ZEON CORPORATION reassignment ZEON CORPORATION CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME, PREVIOUSLY RECORDED AT REEL/FRAME 019686/0049 (ASSIGNOR HEREBY CONFIRMS THE ASSIGNOR'S NAME SHOULD BE READ AS BIOMUNE COMPANY) Assignors: BIOMUNE COMPANY
Priority to CN2008800166743A priority patent/CN101903040A/en
Priority to ES08727197T priority patent/ES2399845T3/en
Priority to JP2010502098A priority patent/JP5508252B2/en
Priority to US12/449,037 priority patent/US8927270B2/en
Priority to EP08727197A priority patent/EP2129390B1/en
Priority to PL08727197T priority patent/PL2129390T3/en
Priority to PCT/US2008/004070 priority patent/WO2008121329A2/en
Priority to BRPI0809529-9A priority patent/BRPI0809529B1/en
Publication of US20080241188A1 publication Critical patent/US20080241188A1/en
Priority to US14/551,487 priority patent/US10072272B2/en
Priority to US16/114,265 priority patent/US10655146B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16441—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Definitions

  • the present invention relates generally to avian vaccines against avian influenza (AI). More specifically, the present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin (HA) protein of avian influenza virus under a promoter.
  • AI avian influenza
  • the present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin (HA) protein of avian influenza virus under a promoter.
  • Avian influenza is caused by avian influenza viruses that are classified in the family Orthomyxoviridae, genus Influenzavirus A.
  • the genome of the avian influenza virus consists of eight segments of single-stranded, negative-sense RNA.
  • the viral genome encodes ten proteins, of which eight proteins are structural proteins including HA and neuraminidase (NA), and two proteins are nonstructural.
  • Influenza A viruses are divided into subtypes based on antigenicity of HA and NA proteins. There are 16 HA antigens and nine NA antigens recognized. HA is considered the major antigen that can elicit protective antibodies in birds.
  • Influenza A viruses from poultry are categorized into two pathotypes based on their pathogenicity: highly pathogenic avian influenza (HPAI) viruses and low pathogenic avian influenza (LPAI) viruses.
  • HPAI highly pathogenic avian influenza
  • LPAI low pathogenic avian influenza
  • Most avian influenza viruses are of low virulence, but a few viruses of H5 and H7 subtypes can cause severe systemic disease that results in high mortality.
  • H5 and H7 avian influenza viruses are of high virulence, all H5 and H7 viruses are identified as notifiable avian influenza virus by World Organization for Animal Health (OIE) because of the risk of low virulent viruses increasing virulence by mutation.
  • OEM World Organization for Animal Health
  • the commercial fowlpox virus vectored recombinant AI vaccine contains the HA gene of the AI virus A/turkey/Ireland/1378/83 (H5N8) (J. R. Taylor et al., 1988, Vaccine, 6: 504-508).
  • HA gene of the AI virus A/turkey/Ireland/1378/83 H5N8
  • Several other experimental fowlpox vectored recombinant vaccines have been developed and shown to be efficacious against challenge with AI viruses in experimental conditions.
  • Avian influenza virus genes contained in the fowlpox vectored recombinant vaccines include the HA gene from A/Chicken/Scotland/59 (H 5 N1) (C. W.
  • H5N1 A/Goose/Guangdond/3/96
  • M. Mingxiao et al. fused the HA genes from H5N1 subtype and H 7 N 1 subtype to form a single open frame and inserted into a recombinant fowlpox virus along with chicken Interleukin-18 (M. Mingxiao et al., 2006, Vaccine, 24: 4304-4311). Broad cross protection among the AI virus H5 subtypes has been observed.
  • the fowlpox virus vectored recombinant AI vaccine and the inactivated whole AI vaccines for avian influenza H5 subtypes have been demonstrated to protect chickens against challenge with diverse H5 subtype AI viruses, of which deduced HA amino acid sequence similarities with the vaccines are as low as 87% (D. E. Swayne et al., 2000, Veterinary Microbiol., 74: 165-172).
  • Next generation vaccines under development include recombinant Newcastle disease virus vaccines (D. E. Swayne et al., 2003, Avian Diseases, 47: 1047-1050; J. Veits et al., 2006, Proc. Natl. Acad. Sci. U.S.A., 103:8197-8202; M. Park et al., 2006, Proc. Natl. Acad. Sci. U.S.A., 103:8203-8208; and J. Ge et al., 2007, J. Virol. 81: 150-158), recombinant infectious laryngotracheitis virus vaccines (D. Luschow et al., 2001, Vaccine 19: 4249-4259 and J.
  • the recombinant Newcastle disease virus vaccines were able to confer partial to semi-complete protection against AI challenge in specific pathogen free chickens, their efficacy in chickens with maternal antibodies to the vector viruses or AI, or in chickens with previous infection or vaccination with the vector viruses remains to be demonstrated.
  • the DNA vaccines have also shown to provide protective immunity in chickens, but they require at least two vaccinations and individual administration to each chicken.
  • the baculovirus-expressed subunit vaccines also require individual administration to each chicken.
  • Turkey herpesvirus (HVT), Marek's disease virus (MDV) serotype-3 has been used as a vector to express antigens from avian pathogens.
  • Wild type HVT or recombinant HVT can be administered to either the late developmental stage of embryos via the in ovo route or one-day-old chicks via the subcutaneous route at hatcheries.
  • Recombinant, cell-associated HVT vaccines after inoculation into embryos or one-day-old chicks with maternal antibodies to inserted antigens, are demonstrated to be able to overcome influences of maternal antibodies and confer protective immunity to chickens as maternal antibodies wane (U.S. Pat. No. 6,764,684 and U.S. Pat. No. 6,866,852).
  • HVT recombinant HVT
  • HVT may be considered an excellent vector for avian pathogens.
  • HVT may be considered an excellent vector for avian pathogens.
  • claim 15 of U.S. Pat. No. 5,853,733 describes the recombinant HVT comprising a polypeptide gene of AI virus inserted within a region which corresponds to an EcoRI #9 fragment of the HVT genome, there is no actual example of constructing recombinant HVT with avian influenza antigens.
  • U.S. Pat. No. 6,225,111 describes construction of recombinant equine herpesviruses containing the HA gene of equine influenza virus, but there is no data about vaccine efficacy of these recombinants.
  • the present invention provides a recombinant HVT modified by the presence of the cDNA encoding the HA protein of avian influenza virus under a promoter.
  • the recombinant HVT is able to elicit a serological response that is easily detected by the HI assay but not by commercially available diagnostic ELISA kits. This feature of the recombinant virus enables easy differentiation between vaccination and field infection.
  • a poultry vaccine comprising the recombinant HVT is also provided.
  • SEQ ID NO: 1 differs from the published nucleotide sequence of the HA gene of the A/Turkey/Wisconsin/68 (H5N9) strain (M. Garcia et al., 1997, Virus Res. 51: 115-124, GenBank Accession# U79456) by several bases. These differences are probably due to the genetically unstable nature of avian influenza viruses, which have an RNA genome. Therefore, the sequence shown in SEQ ID NO: 1 is only an example and the present invention should not be restricted to the sequence.
  • a regulatory DNA sequence which is referred to here as a promoter, is included in order to control transcription of the HA gene, and thereby to control expression of the HA gene (generation of the HA protein).
  • a promoter When transcription and thereby expression of a gene is controlled by a promoter, the gene is considered under control of the promoter.
  • the HA gene is under control of the cytomegalovirus immediate early promoter (CMV promoter).
  • recombinant HVT with the HA gene in combination with the CMV promoter was capable of conferring higher and more uniform serology titers by HI in chickens than the recombinant HVT with other promoters such as the chicken beta-actin promoter (T. A. Kost et al., 1983, Nucleic Acids Res. 11:8287-8301) and a modified chicken beta-actin promoter (U.S. Pat. No. 6,866,852).
  • a nucleotide sequence of the CMV promoter is described in the literature (M. Boshart et al., 1985, Cell 41: 521-530, GenBank Accession# K03104).
  • the nucleotide sequence of a promoter does not have to be identical to the sequence in the literature.
  • the CMV promoter the sequence of which is shown in SEQ ID NO: 3, is slightly modified from the original sequence by the inventors, but was demonstrated to express the HA gene effectively.
  • Turkey herpesvirus is a double-stranded linear DNA virus in the Herpesviridae family and Alphaherpesvirinae subfamily.
  • HVT is ubiquitous and non-oncogenic in domestic turkeys and it is classified as serotype 3 of Marek's disease virus.
  • Vaccination of chickens with HVT has been extensively conducted to prevent Marek's disease in chickens.
  • any HVT can be used in the present invention.
  • the following HVT strains, FC126, PB-THV1, H-2, YT-7, WTHV-1, and HPRS-26 are suitable for the backbone virus.
  • the FC126 strain is favorable for use in the present invention.
  • the HA gene and the CMV promoter are inserted into an HVT DNA genome.
  • the HA gene and the CMV promoter are inserted into a region in the HVT genome that is not essential for virus growth, which is referred to here as a non-essential region.
  • a non-essential region may be defined as a region where modification or insertion of a foreign gene does not prevent the virus from replicating successfully in vitro or in vivo.
  • the HA gene and the CMV promoter can be inserted into, but not limited to UL43 (WO 89/01040), US2 (WO 93/25665) or inter-ORF region between UL44 and UL46 (WO 99/18215). Most preferably, the HA gene and the CMV promoter are inserted into the inter-ORF region between UL45 and UL46.
  • a non-essential region may be newly identified by the following general procedure.
  • HVT DNA fragments of appropriate lengths are cloned into an E. coli plasmid and physically mapped by restriction enzyme analysis.
  • a gene cassette consisting of a promoter and a marker gene is inserted into an appropriate restriction site of the cloned DNA fragment resulting in a homology plasmid. If homologous recombination with the obtained homology plasmid results in a recombinant virus expressing the inserted marker gene and if the virus is stable in vitro and in vivo, the originally selected DNA fragment should be a non-essential region suitable for HA gene and CMV promoter insertion.
  • any known method of generating recombinant HVT is applicable.
  • a typical example is as follows. (1) First, as described above, a recombinant plasmid that contains a non-essential region of the HVT genome is constructed. Then, preferably with a promoter at the 5′ terminus and a polyadenylation signal at the 3′ terminus, the HA gene is inserted into the non-essential region to generate a homology plasmid. (2) The homology plasmid is transfected into chicken embryo fibroblast (CEF) cells infected with parent HVT or co-transfected into CEF cells with infectious HVT genomic DNA. Transfection can be performed by any known method.
  • CEF chicken embryo fibroblast
  • the transfected CEF cells are planted on tissue culture plates and incubated until virus plaques become visible.
  • the identifiable plaques include recombinant virus as well as parent wild-type virus.
  • the recombinant virus may be purified from wild type virus by any known method to detect expression of inserted foreign genes.
  • the recombinant HVT containing the HA gene in the present invention may be used as a bivalent vaccine against AI and Marek's disease or as a monovalent vaccine against AI.
  • the vaccine consisting mainly of the recombinant HVT in the present invention, may also include avian cells, ingredients of culture media, buffers such as a phosphate buffer and HEPES buffer, and/or adjuvants such as cytokines and CpG oligodeoxynucleotide. As long as not pharmacologically detrimental, the vaccine may contain any ingredients such as preservatives.
  • the vaccine of the present invention can be used in a mixture with any recombinant or non-recombinant viruses such as the MDV serotype I or serotype 2 vaccine strains.
  • the recombinant HVT may be inoculated into permissive culture cells such as CEF cells and grown to an appropriate titer. Then, the cells are removed from tissue culture plates or roller bottles with cell scrapers or by trypsin treatment and collected by centrifugation. The pelleted cells are then suspended in culture medium containing dimethyl sulfoxide, frozen slowly, and then stored in liquid nitrogen.
  • the recombinant HVT may be released from the infected cells by disrupting the cells in diluents containing stabilizers such as sucrose and bovine albumin. These released HVT is called cell-free HVT. Cell-free HVT may be lyophilized and stored at 4° C.
  • the bivalent recombinant HVT vaccine can be administered to chickens by any known method of inoculating Marek's disease vaccine.
  • the vaccine of the present invention is diluted to give 10 1 -10 5 , or more favorably 10 2 -10 4 plaque forming units (pfu) per dose with a diluent containing buffer components, sugars, and dye.
  • the diluted vaccine may be inoculated subcutaneously behind the neck of one-day-old chicks or into embryonating eggs via the in ovo route with syringes or with any apparatus for injection.
  • the present avian bivalent vaccine is able to confer serological titer by HI of more than 50 (geometric mean titer) in groups of vaccinated chickens by 5 weeks post inoculation, when using four hemagglutination units of an inactivated avian influenza virus homologous H5 subtype antigen for the HI tests.
  • FIG. 1 Construction of the plasmid pGICMVpA
  • FIG. 2 Construction of the homology plasmid p45CMVH5Wis68
  • FIG. 3 Construction of the plasmid pGIBacpA2nd
  • FIG. 4 Construction of the homology plasmid p45BacH5Wis68
  • FIG. 5 Construction of the homology plasmid p45PecH5Wis68
  • FIG. 6 Western blot assay detecting expression of the hemagglutinin protein by the recombinant turkey herpesvirus
  • FIG. 7 Hemagglutination inhibition titers in chickens vaccinated with the recombinant turkey herpesvirus with hemagglutinin gene
  • FIG. 8 ELISA titers in chickens vaccinated with the recombinant turkey herpesvirus with hemagglutinin gene using a commercial ELISA kit (IDEXX LABORATORIES, FLOCKCHEK AIV)
  • FIG. 9 ELISA titers in chickens vaccinated with the recombinant turkey herpesvirus with hemagglutinin gene using a commercial ELISA kit (SYNBIOTICS, PROFLOK AIV Ab test kit)
  • the avian influenza virus A/Turkey/Wisconsin/68 (H5N9) strain was propagated in the allantoic sac of specific pathogen free embryonating chicken eggs.
  • Total genomic RNA from the A/Turkey/Wisconsin/68 virus was extracted using RNEASY MINI KIT (QIAGEN, Cat# 74104).
  • First-strand cDNA was synthesized with SUPERSCRIPT FIRST-STRAND System for RT-PCR (Invitrogen, Cat# 11904-018).
  • the HA gene was amplified by polymerase chain reaction (PCR) with PFUULTRA HIGH FIDELITY DNA Polymerase (STRATAGENE, Cat# 600380) and PCR primers.
  • PCR primers BamHA-F primer (SEQ ID NO: 4) and SalHA-R primer (SEQ ID NO: 5), anneal to the start and stop sequences of the HA gene and each primer contains a sequence at the 5′ ends for a restriction enzyme, BamHI or SalI, respectively.
  • Taq polymerase PROMEGA, Cat# M2665 was added to the PCR mixture to add 3′ A-overhangs to the PCR products.
  • BamHA-F primer (SEQ ID NO: 4) 5′-TGACGGATCCATGGAAAGAATAGTGATTG-3′ SalHA-R primer (SEQ ID NO: 5) 5′-CTGACAGTCGACCTAGATGCAAATTCTGC-3′
  • the amplified 1.8 kilobase (kb) HA cDNA was inserted into PCR2.1-TOPO vector (INVITROGEN, Cat# K4500-01), resulting in pCR2.1-H5Wis68.
  • Nucleotide sequences of the HA genes in a few clones of the plasmid pCR2.1-H5Wis68 and the PCR product were determined using ABI PRISM 3730XL DNA Analyzer (APPLIED BIOSYSTEMS) with six primers; BamHA-F primer (SEQ ID NO: 4), SalHA-R primer (SEQ ID NO: 5), M13 Forward primer (SEQ ID NO: 6), M13 Reverse primer (SEQ ID NO: 7), HA-F primer (SEQ ID NO: 8), and HA-R primer (SEQ ID NO: 9).
  • the sequences in the clones of the plasmid pCR2.1-H5Wis68 were identical to each other and to the sequence of the PCR product.
  • the deduced amino acid sequence was different from the reported sequence of A/Turkey/Wisconsin/68 (H5N9) (M. Garcia et al., 1997, Virus Res. 51: 115-124, GenBank Accession# U79456) by four amino acids, the amino acids we obtained were the same as the amino acids of a majority of H5 subtype HA proteins.
  • the nucleotide sequence and the deduced amino acid sequence of the HA gene obtained from A/Turkey/Wisconsin/68 (H5N9) are shown in SEQ ID NO: 1 and SEQ ID NO: 2.
  • three promoters the CMV promoter, the chicken beta-actin promoter (Bac promoter), and a modified chicken beta-actin promoter (Pec promoter), were used to control expression of the HA gene of the AI virus A/Turkey/Wisconsin/68 (H5N9) strain.
  • homology plasmids with the HA gene and one of the promoters were constructed and then recombinant turkey herpesviruses were generated using the homology plasmids.
  • the recombinant turkey herpesviruses with different promoters were compared for capabilities of conferring serological titers against AI in chickens as shown in EXAMPLE 6.
  • a recombinant HVT with the CMV promoter is presented here as an example and recombinant viruses with the Bac promoter or the Pec promoter are presented here as comparative examples.
  • a list of the homology plasmids and the recombinant turkey herpesviruses constructed in the present invention is shown in TABLE 1.
  • the CMV promoter was obtained from pBK-CMV (STRATAGENE, Cat. #212209). Three BglI restriction enzyme sites in the CMV promoter were disrupted for ease of the plasmid construction process by PCR in vitro mutagenesis using four pairs of primers.
  • the primer pairs were PrCMV1 (SEQ ID NO: 10) and PrCMV3 (SEQ ID NO: 12), PrCMV4 (SEQ ID NO: 13) and PrCMV5 (SEQ ID NO: 14), PrCMV6 (SEQ ID NO: 15) and PrCMV2′ (SEQ ID NO: 11), and PrCMVo1 (SEQ ID NO: 16) and PrCMVR1 (SEQ ID NO: 17).
  • PCR reactions were conducted separately using each pair of primers and pBK-CMV as a template. Then four PCR products were combined and used as a template for the secondary PCR with primers PrCMV1 and PrCMVR1, yielding the 604 bp fragment with a modified CMV promoter sequence.
  • the nucleotide sequence of the CMV promoter used to express HA gene is provided in SEQ ID. NO. 3.
  • the CMV promoter fragment was digested with PstI and XbaI and inserted into PstI and XbaI digested pUC18polyASfi (U.S. Pat. No. 6,866,852), resulting in pGICMV( ⁇ ).
  • the SV40 polyA signal was obtained from pBK-CMV by PCR using primers PolyA-SalKpn (SEQ ID NO: 18) and PolyA-SfiF2 (SEQ ID NO: 19).
  • the PCR fragment containing SV40 polyA signal was digested with SalI and SfiI and ligated to pGICMV( ⁇ ) digested with SalI and SfiI resulting in pGICMVpA ( FIG. 1 ).
  • PrCMV1 (SEQ ID NO: 10) 5′-GGGCTGCAGAGTTATTAATAGTAATCAATT-3′ PrCMV2′ (SEQ ID NO: 11) 5′-CGCGCCATTTACCGTCATTGACGTC-3′ PrCMV3 (SEQ ID NO: 12) 5′-GGGTCGTTGGGCGGTCAGCCGGCGG-3′ PrCMV4 (SEQ ID NO: 13) 5′-CTTACGGTAAATGGCCCGCCGGCTG-3′ PrCMV5 (SEQ ID NO: 14) 5′-TACACTTGATGTACTGCCAATGGGC-3′ PrCMV6 (SEQ ID NO: 15) 5′-TATTTACGGTAAACTGCCCATTGGC-3′ PrCMVo1 (SEQ ID NO: 16) 5′-ACGTCAATGACGGTAAATGGCGCGCCTGGC-3′ PrCMVR1 (SEQ ID NO: 17) 5′-CGTCTAGAGGATCTGACGGTTCACTAAACC-3′ PolyA-SalKpn (S
  • the CMV promoter and the SV40 polyA signal (940 bp) were excised from pGICMVpA by BglI and ligated into SfiI digested p45/46Sfi (U.S. Pat. No. 6,866,852), resulting in p45/46CMVpA.
  • the HA gene from A/Turkey/Wisconsin/68 H5N9 was excised from pCR2.1-H5Wis68 using SalI and BamHI.
  • the 1701 bp HA gene was inserted into p45/46CMVpA digested with SalI and BamHI, resulting in p45CMVH5Wis68 ( FIG. 2 ).
  • the plasmid p45CMVH5Wis68 was used as a homology plasmid to generate recombinant turkey herpesvirus.
  • the Bac promoter was obtained by PCR using cellular DNA of CEF cells as a template.
  • PrBac1 SEQ ID NO: 18
  • PrBac2′ SEQ ID NO: 19
  • An obtained 1.5-kilobase DNA fragment was digested with PstI and XbaI and inserted into PstI and XbaI digested pUC18polyASfi, resulting in pGIBac2.
  • the SV40 polyA signal obtained PCR using primers PolyA-SalKpn (SEQ ID NO: 18) and PolyA-SfiF2 (SEQ ID NO: 19) was digested with SalI and SfiI and ligated to pGIBac2 digested with SalI and SfiI resulting in pGIBacpA2nd ( FIG. 3 ).
  • PrBac1 (SEQ ID NO: 20) 5′-CAGTGTCGCTGCAGCTCAGTGCATGCACGCTCATTGCCC-3′
  • PrBac2′ (SEQ ID NO: 21) 5′- GCTCTAGAGGCGTGGAGCTTGGGGGCTGCGGAGGAACAGAGAAGGGAAG- 3′ 2-5. Construction of Homology Plasmid p45BaCH 5 Wis68
  • the Bac promoter and the SV40 polyA signal (1866 bp) were excised from pGIBacpA2nd by BglI and ligated into SfiI digested p45/46Sfi, resulting in p45/46BacpA2nd. Then, the HA gene of A/Turkey/Wisconsin/68 (H5N9) excised from pCR2.1-H5Wis68 using SalI and BamHI was inserted into p45/46BacpA2nd digested with SalI and BamHI, resulting in p45BaCH 5 Wis68 ( FIG. 4 ).
  • Pec promoter Construction of the Pec promoter is described in U.S. Pat. No. 6,866,852.
  • the Pec promoter was synthesized by fusing a part of the chicken beta-actin promoter with the enhancer region of the CMV promoter.
  • the Pec promoter was excise from pGIPec (U.S. Pat. No. 6,866,852) with PstI and BamHI and inserted into PstI and BamHI digested p45/46BacpA2nd described in EXAMPLE 2-4, resulting in p45/46PecpA2nd.
  • H5N9 A/Turkey/Wisconsin/68 excised from pCR2.1-H5Wis68 using SalI and BamHI was inserted into p45/46PecpA2nd digested with SalI and BamHI, resulting in p45PeCH 5 Wis68 ( FIG. 5 ).
  • Viral DNA of the HVT FC126 strain was prepared as described by Morgan et al. (Avian Diseases, 1990, 34:345-351).
  • the cells were detached from the plates by trypsinization, transferred equally to two 96-well plates with secondary CEF and incubated for 3 to 4 days until plaques were observed. Screening was conducted by the black plaque assay, staining only plaques expressing HA protein. Briefly, one of the two plates was fixed with methanol:acetone mixture (1:2) and incubated with chicken anti-HA antiserum.
  • Chicken embryo fibroblast cells in a 100-mm dish that were infected with the recombinant virus, rHVT/CMVH5Wis68 or the HVT FC126 parent strain were used in the Southern blot analysis to confirm the insertion of the HA gene in the desired insertion site.
  • the cells were collected by a cell scraper and by centrifugation at 913 ⁇ g for 5 minutes.
  • the harvested cells were washed with phosphate buffered saline (PBS) and resuspended in 1.0 milliliter (ml) of lysis buffer (0.5% TRITON X-100, 100 mM 2-mercaptethanol, and 20 mM EDTA in PBS).
  • the cell suspension was vortexed for a total of 30 seconds and incubated for 15 minutes at room temperature.
  • Cell nucleus and cell debris were removed by centrifuging at 2,060 ⁇ g for 5 minutes and the supernatant was transferred to a 1.5-ml tube.
  • Viruses were collected by centrifugation at 20,800 ⁇ g for 20 minutes at 4° C.
  • the pellet was suspended in 0.33 ml of a nuclease solution (12.5 mM Tris-Cl (pH7.5), 1 ⁇ g/ml DNase I and 1 ⁇ g/ml RNase A) and incubated at 37° C. for 30 minutes.
  • SDS-protease solution 50 mM EDTA, 5% SDS, 0.5 mg/ml protease K, and 25 mM 2-mercaptoethanol
  • 50 mM EDTA, 5% SDS, 0.5 mg/ml protease K, and 25 mM 2-mercaptoethanol was added to the virus suspension and incubated at 55° C. for 30 minutes to disrupt virus envelopes.
  • Phenol chloroform extraction was conducted twice and DNA was precipitated by adding 2.5 volume of cold 100% ethanol and NaCl at a final concentration of 0.16 M. After centrifuging at 20,800 ⁇ g for 30 minutes at 4° C., the pellet washed with 70% ethanol and air-dried. The pellet was dissolved in TE buffer (10 mM Tris-Cl (pH8.0), and 1 mM EDTA).
  • the DIG-labeled HA probe and the IS45/46 probe were prepared with PCR DIG Probe Synthesis Kit (ROCHE APPLIED SCIENCE, Cat# 11636090910) using primers HA1-P-F (SEQ ID NO: 22) and HA1-P-R (SEQ ID NO: 23) and primers 45/46-F (SEQ ID NO: 24) and 45/46-R (SEQ ID NO: 25), respectively.
  • HA1-P-F (SEQ ID NO: 22) 5′-GGGGGTGGCAAGGAATG-3′ HA1-P-R (SEQ ID NO: 23) 5′-GCTAGGGAACTCGCCACTGT-3′ 45/46-F-B (SEQ ID NO: 24) 5′-TAGCGGCACGGAAACAGATAGAGA-3′ 45/46-R-B (SEQ ID NO: 25) 5′-TGGCGATACGGTTCCTGGTTTGAC-3′
  • the membrane washed with 2 ⁇ SSC solution at room temperature and then with 0.5 ⁇ SSC solution at 68° C.
  • the membrane was blocked and incubated with anti-Digoxigenin-AP, Fab fragments (ROCHE APPLIED SCIENCE, Cat# 11093274910) for 30 minutes at room temperature.
  • maleic acid washing buffer 0.1 M maleic acid, 0.15 M NaCl, and 0.3% Tween20, pH 7.5
  • DNA bands that were hybridized with the probes were visualized by incubating the membrane with BCIP/NBT solution.
  • the HA probe hybridized with 3.6 kb bands in the recombinant virus DNA and the homology plasmid, while no bands were detected with the HVT parent.
  • the HA probe hybridized with 3.6 kb bands in the recombinant virus DNA and the homology plasmid, while no bands were detected with the HVT parent.
  • the IS45/46 probe hybridized with 3.6 kb and 1.2 kb bands in the recombinant DNA and the homology plasmid, and with 2.3 kb band in the HVT parent.
  • the recombinant viruses were passed 20 times blindly in CEF cells. After the 20 passages, the viruses were analyzed by the Southern blot analysis as described in EXAMPLE 4.1. Bands detected in DNA isolated from the virus after 20 passages were identical to the bands described in EXAMPLE 4.1, demonstrating that the recombinant viruses were stable even after 20 passages.
  • HA protein by the recombinant viruses, rHVT/CMVH5Wis68, rHVT/BaCH5Wis68, and rHVT/PeCH5Wis68, was confirmed by the black plaque assay and the Western blot assay. Procedures for the black plaque assay are described in EXAMPLE 3. The western blot was conducted using CEF cells infected with the recombinant viruses and chicken anti-HA antiserum. Briefly, CEF cells in 100-mm dishes were infected with one of the recombinant viruses or the parent HVT FC126 strain at a multiplicity of infection of approximately 0.01.
  • the membrane was incubated with alkaline phosphatase-conjugated anti-chicken IgG Fc antibody (BETHYL, Cat# A30-104AP). Protein bound with chicken anti-HA antiserum was visualized by adding BCIP/NBT solution. As shown in FIG. 3 , a protein band of 74 kilodaltons (kDa) was observed only in the lane with the recombinant virus infected cells, which was the expected size of the non-processed HA protein.
  • alkaline phosphatase-conjugated anti-chicken IgG Fc antibody BETHYL, Cat# A30-104AP
  • Groups 1 and 2 were inoculated with 1638 pfu per dose (0.2 ml) and 375 pfu per dose of rHVT/CMVH5Wis68, respectively (TABLE 2).
  • Groups 3 and 4 contained chickens vaccinated with 2800 pfu (Group 3) or 550 pfu (Group 4) of rHVT/PeCH5Wis68. Groups 5 and 6 were inoculated with 4350 pfu and 720 pfu per dose of rHVT/BacH5Wis68, respectively. A group of chickens (Group 8) were held as non-inoculated negative controls. Another group of chickens (Group 7) was vaccinated subcutaneously with inactivated A/Turkey/Wisconsin/68 (H5N9) vaccine at three weeks old as an inactivated vaccine control.
  • Chickens were bled between 3 to 7 weeks old and obtained sera were evaluated by the AI HI tests and AIV ELISA tests.
  • the AI HI tests were conducted using four hemagglutination units of an inactivated avian influenza virus homologous antigen of the A/Turkey/Wisconsin/68 (H5N9) strain, the HA gene of which was used in the recombinant viruses, as described by D. E. Swayne et al. (D. E. Swayne et al., 1998, Avian Influenza. In: A Laboratory Manual for the Isolation and Identification of Avian Pathogens, 150-155).
  • the number of the hemagglutination units in the inactivated A/Turkey/Wisconsin/68 (H5N9) antigen was determined as the highest dilution of the antigen giving complete agglutination, and the antigen was diluted to contain four hemagglutination units in 25 ⁇ l.
  • the sera were initially diluted 1:5 and then serially diluted by two fold across the plates with phosphate buffered saline (PBS) to contain 25 ⁇ l per well.
  • PBS phosphate buffered saline
  • HI titers are the highest dilution of the sera exhibiting inhibition of hemagglutination. HI titers of equal to or more than 10 were considered positive.
  • the ELISA tests were conducted using two commercial AIV ELISA kits (IDEXX Laboratories, FLOCKCHEK AIV and SYNBIOTICS, PROFLOK AIV Ab test kit) that are available in the United States.
  • the recombinant HVT with the HA gene in combination with the CMV promoter provided vaccinated chickens with higher and more uniform serology titers by HI than the recombinant HVT with the Bac promoter (rHVT/BacH5Wis68) and the recombinant HVT with the Pec promoter (rHVT/PecH5Wis68), which are presented here as comparative examples.
  • the sera collected from chickens vaccinated from rHVT/CMVH5Wis68 were negative by commercially available AIV ELISA kits although the sera were highly positive by the AI HI tests, thus enabling easy differentiation between reaction from vaccination and field infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the hemagglutination inhibition assay but not by commercially available diagnostic ELISA kits; thus enabling easy differentiation between vaccination and field infection.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • Not applicable.
    • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • Not applicable.
    • THE NAMES OF PARTIES TO A JOINT RESEARCH AGREEMENT
  • The following are parties to a joint research agreement effective Jun. 15, 2005: Biomune Company (a Kansas general partnership), Zeon Corporation (Japan) and Ceva Sante Animale S. A. (France).
    • REFERENCE TO SEQUENCE LISTING
  • The Sequence Listing in the file named “070161 Sequence Listing” on the one concurrently submitted Compact Disk is hereby incorporated by reference.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates generally to avian vaccines against avian influenza (AI). More specifically, the present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin (HA) protein of avian influenza virus under a promoter.
  • 2. Description of the Related Art
  • Avian influenza is caused by avian influenza viruses that are classified in the family Orthomyxoviridae, genus Influenzavirus A. The genome of the avian influenza virus consists of eight segments of single-stranded, negative-sense RNA. The viral genome encodes ten proteins, of which eight proteins are structural proteins including HA and neuraminidase (NA), and two proteins are nonstructural. Influenza A viruses are divided into subtypes based on antigenicity of HA and NA proteins. There are 16 HA antigens and nine NA antigens recognized. HA is considered the major antigen that can elicit protective antibodies in birds.
  • Influenza A viruses from poultry are categorized into two pathotypes based on their pathogenicity: highly pathogenic avian influenza (HPAI) viruses and low pathogenic avian influenza (LPAI) viruses. Most avian influenza viruses are of low virulence, but a few viruses of H5 and H7 subtypes can cause severe systemic disease that results in high mortality. Although only a few H5 and H7 avian influenza viruses are of high virulence, all H5 and H7 viruses are identified as notifiable avian influenza virus by World Organization for Animal Health (OIE) because of the risk of low virulent viruses increasing virulence by mutation.
  • Since the late 1990s, there has been a significant increase in the number of AI outbreaks and in the number of birds involved in those outbreaks (I. Capua et al., 2004, Avian Pathology, 33: 393-404). The most notable example is a series of H5N1 HPAI outbreaks in China and South-East Asia, which has now spread to other parts of the world such as Europe, the Middle East, and Africa. The outbreaks have cost as many as 160 human lives in more than 10 countries since 2003 although apparent human-to-human transmission has yet to be confirmed. These recent outbreaks have caused tremendous economic losses to the poultry industry and raised public concerns because of fear of a possible human pandemic.
  • Vaccination against AI had not been conducted extensively until recently because the so-called “stamping-out” procedure has been the primary option. In the “stamping-out” procedure, all chickens in flocks infected with AI are culled. Most AI outbreaks were eradicated or controlled by “stamping-out” in the past. However, in recent AI outbreaks, especially in the H5N1 outbreaks, there have been situations in which massive culling was not practical or feasible due to intolerable economic costs and losses associated with the culling, widespread presence of so-called backyard chickens, and so forth. In those situations, vaccination has been considered a suitable and powerful tool to support AI eradication or AI control programs because vaccination has been shown to protect poultry against clinical signs and death and reduce virus shedding in vaccinated birds, thereby reducing transmission of virus (D. E. Swayne., 2003, Developments in Biologicals, 114: 201-212). In order to utilize vaccines in AI eradication programs or AI control programs, it is critical for trade and surveillance purposes that vaccinated birds may be differentiated from those infected with the field virus. In fact, field exposure in vaccinated flocks must be detected in simple serological assays. Otherwise, the field virus may circulate in the vaccinated birds undetected. It is also important that evidence of vaccination may be detected by simple assays in order to confirm that most or all birds in vaccinated flocks are properly vaccinated.
  • Commercial vaccines currently available are inactivated whole AI antigens with oil adjuvant and a fowlpox virus vectored recombinant vaccine. Although both vaccines have been shown to be efficacious, they require labor-intensive and expensive parenteral vaccination that involves handling each bird manually. While the inactivated AI vaccines have been used in the program called DIVA (“Differentiation of infected from vaccinated animals”), there have been no commercially available tests developed for mass application. It has been shown that chickens pre-immunized with fowlpox virus either by field exposure or by vaccination with conventional fowlpox vaccines would not develop consistent protective immunity against AI after vaccinated with the fowlpox virus vectored recombinant AI vaccine (D. E. Swayne et al., 2000, Avian Diseases, 44: 132-137). The fowlpox virus vectored recombinant AI vaccine has failed to elicit serological response detectable by the hemagglutination inhibition (HI) test consistently (D. E. Swayne et al., 1997, Avian Diseases, 41: 910-922). Hence, development of vaccines that are easier to administer and that may be readily differentiated from field virus infection is desirable for the poultry industry.
  • The commercial fowlpox virus vectored recombinant AI vaccine contains the HA gene of the AI virus A/turkey/Ireland/1378/83 (H5N8) (J. R. Taylor et al., 1988, Vaccine, 6: 504-508). Several other experimental fowlpox vectored recombinant vaccines have been developed and shown to be efficacious against challenge with AI viruses in experimental conditions. Avian influenza virus genes contained in the fowlpox vectored recombinant vaccines include the HA gene from A/Chicken/Scotland/59 (H5N1) (C. W. Beard et al., 1991, Avian Diseases, 35: 356-359) and the HA and NA genes from A/Goose/Guangdond/3/96 (H5N1) (C. Qiao et al., 2003, Avian Pathol., 32:25-31). M. Mingxiao et al. fused the HA genes from H5N1 subtype and H7N1 subtype to form a single open frame and inserted into a recombinant fowlpox virus along with chicken Interleukin-18 (M. Mingxiao et al., 2006, Vaccine, 24: 4304-4311). Broad cross protection among the AI virus H5 subtypes has been observed. The fowlpox virus vectored recombinant AI vaccine and the inactivated whole AI vaccines for avian influenza H5 subtypes have been demonstrated to protect chickens against challenge with diverse H5 subtype AI viruses, of which deduced HA amino acid sequence similarities with the vaccines are as low as 87% (D. E. Swayne et al., 2000, Veterinary Microbiol., 74: 165-172).
  • Next generation vaccines under development include recombinant Newcastle disease virus vaccines (D. E. Swayne et al., 2003, Avian Diseases, 47: 1047-1050; J. Veits et al., 2006, Proc. Natl. Acad. Sci. U.S.A., 103:8197-8202; M. Park et al., 2006, Proc. Natl. Acad. Sci. U.S.A., 103:8203-8208; and J. Ge et al., 2007, J. Virol. 81: 150-158), recombinant infectious laryngotracheitis virus vaccines (D. Luschow et al., 2001, Vaccine 19: 4249-4259 and J. Veits et al., 2003, J. Gen. Virol. 84: 3343-3352), a recombinant adenovirus vaccine (W. Gao et al., 2006, J. Virol. 80: 1959-1964), baculovirus-expressed subunit vaccines (J. Crawford et al., 1999, Vaccine, 17:2265-2274 and D. E. Swayne et al., 2001, Avian Diseases, 45: 355-365) and DNA vaccines (U.S. Pat. No. 5,916,879 and M. Cherbonnel et al., 2003, Avian Diseases, 47: 1181-1186). Although the recombinant Newcastle disease virus vaccines, the recombinant infectious laryngotracheitis virus vaccines, and the recombinant adenovirus vaccine were able to confer partial to semi-complete protection against AI challenge in specific pathogen free chickens, their efficacy in chickens with maternal antibodies to the vector viruses or AI, or in chickens with previous infection or vaccination with the vector viruses remains to be demonstrated. The DNA vaccines have also shown to provide protective immunity in chickens, but they require at least two vaccinations and individual administration to each chicken. The baculovirus-expressed subunit vaccines also require individual administration to each chicken.
  • Turkey herpesvirus (HVT), Marek's disease virus (MDV) serotype-3, has been used as a vector to express antigens from avian pathogens. Wild type HVT or recombinant HVT can be administered to either the late developmental stage of embryos via the in ovo route or one-day-old chicks via the subcutaneous route at hatcheries. Recombinant, cell-associated HVT vaccines, after inoculation into embryos or one-day-old chicks with maternal antibodies to inserted antigens, are demonstrated to be able to overcome influences of maternal antibodies and confer protective immunity to chickens as maternal antibodies wane (U.S. Pat. No. 6,764,684 and U.S. Pat. No. 6,866,852). Excellent duration of immunity is also achieved by recombinant HVT (U.S. Pat. No. 6,866,852) probably because HVT goes latent and stays inside vaccinated birds for their whole life. Thus, HVT may be considered an excellent vector for avian pathogens. There have been no reports of constructing recombinant HVT or MDV with avian influenza antigens. Although claim 15 of U.S. Pat. No. 5,853,733 describes the recombinant HVT comprising a polypeptide gene of AI virus inserted within a region which corresponds to an EcoRI #9 fragment of the HVT genome, there is no actual example of constructing recombinant HVT with avian influenza antigens. In mammalian species, U.S. Pat. No. 6,225,111 describes construction of recombinant equine herpesviruses containing the HA gene of equine influenza virus, but there is no data about vaccine efficacy of these recombinants.
    • BRIEF SUMMARY OF THE INVENTION
  • The present invention provides a recombinant HVT modified by the presence of the cDNA encoding the HA protein of avian influenza virus under a promoter. The recombinant HVT is able to elicit a serological response that is easily detected by the HI assay but not by commercially available diagnostic ELISA kits. This feature of the recombinant virus enables easy differentiation between vaccination and field infection. A poultry vaccine comprising the recombinant HVT is also provided.
  • The present invention is described below in more detail.
    • (Avian Influenza Virus Hemagglutinin Gene)
  • The hemagglutinin gene may be obtained from any subtype or any strain of avian influenza virus. Preferably, the HA gene is obtained from an avian influenza virus of the H5 subtype. More preferably, the HA gene is obtained from avian influenza virus of the H5N9 subtype. Most preferably, the HA gene is obtained from the avian influenza virus A/Turkey/Wisconsin/68 (H5N9) strain. A nucleotide sequence of the HA gene from the A/Turkey/Wisconsin/68 (H5N9) strain is shown in SEQ ID NO: 1. The sequence in SEQ ID NO: 1 differs from the published nucleotide sequence of the HA gene of the A/Turkey/Wisconsin/68 (H5N9) strain (M. Garcia et al., 1997, Virus Res. 51: 115-124, GenBank Accession# U79456) by several bases. These differences are probably due to the genetically unstable nature of avian influenza viruses, which have an RNA genome. Therefore, the sequence shown in SEQ ID NO: 1 is only an example and the present invention should not be restricted to the sequence.
    • (Promoter)
  • Adjacent to the HA gene in an HVT genome, typically at the 5′ region of the HA gene, a regulatory DNA sequence, which is referred to here as a promoter, is included in order to control transcription of the HA gene, and thereby to control expression of the HA gene (generation of the HA protein). When transcription and thereby expression of a gene is controlled by a promoter, the gene is considered under control of the promoter. In the present invention, the HA gene is under control of the cytomegalovirus immediate early promoter (CMV promoter). We found that recombinant HVT with the HA gene in combination with the CMV promoter was capable of conferring higher and more uniform serology titers by HI in chickens than the recombinant HVT with other promoters such as the chicken beta-actin promoter (T. A. Kost et al., 1983, Nucleic Acids Res. 11:8287-8301) and a modified chicken beta-actin promoter (U.S. Pat. No. 6,866,852). A nucleotide sequence of the CMV promoter is described in the literature (M. Boshart et al., 1985, Cell 41: 521-530, GenBank Accession# K03104). However, as long as a promoter is functional in cells or in the bodies of avian species, the nucleotide sequence of a promoter does not have to be identical to the sequence in the literature. The CMV promoter, the sequence of which is shown in SEQ ID NO: 3, is slightly modified from the original sequence by the inventors, but was demonstrated to express the HA gene effectively.
    • (Turkey Herpesvirus)
  • Turkey herpesvirus is a double-stranded linear DNA virus in the Herpesviridae family and Alphaherpesvirinae subfamily. HVT is ubiquitous and non-oncogenic in domestic turkeys and it is classified as serotype 3 of Marek's disease virus. Vaccination of chickens with HVT has been extensively conducted to prevent Marek's disease in chickens. As long as it is non-pathogenic to chickens, any HVT can be used in the present invention. For instance, the following HVT strains, FC126, PB-THV1, H-2, YT-7, WTHV-1, and HPRS-26, are suitable for the backbone virus. Among these, the FC126 strain is favorable for use in the present invention.
    • (Region for Gene Insertion)
  • In the present invention, the HA gene and the CMV promoter are inserted into an HVT DNA genome. Preferably, the HA gene and the CMV promoter are inserted into a region in the HVT genome that is not essential for virus growth, which is referred to here as a non-essential region. In other words, a non-essential region may be defined as a region where modification or insertion of a foreign gene does not prevent the virus from replicating successfully in vitro or in vivo. Several non-essential regions in the HVT genome have been reported. For instance, the HA gene and the CMV promoter can be inserted into, but not limited to UL43 (WO 89/01040), US2 (WO 93/25665) or inter-ORF region between UL44 and UL46 (WO 99/18215). Most preferably, the HA gene and the CMV promoter are inserted into the inter-ORF region between UL45 and UL46.
  • For the present invention, a non-essential region may be newly identified by the following general procedure. First, HVT DNA fragments of appropriate lengths are cloned into an E. coli plasmid and physically mapped by restriction enzyme analysis. Then, a gene cassette consisting of a promoter and a marker gene is inserted into an appropriate restriction site of the cloned DNA fragment resulting in a homology plasmid. If homologous recombination with the obtained homology plasmid results in a recombinant virus expressing the inserted marker gene and if the virus is stable in vitro and in vivo, the originally selected DNA fragment should be a non-essential region suitable for HA gene and CMV promoter insertion.
  • (Construction of rHVT)
  • For the present invention, any known method of generating recombinant HVT is applicable. A typical example is as follows. (1) First, as described above, a recombinant plasmid that contains a non-essential region of the HVT genome is constructed. Then, preferably with a promoter at the 5′ terminus and a polyadenylation signal at the 3′ terminus, the HA gene is inserted into the non-essential region to generate a homology plasmid. (2) The homology plasmid is transfected into chicken embryo fibroblast (CEF) cells infected with parent HVT or co-transfected into CEF cells with infectious HVT genomic DNA. Transfection can be performed by any known method. (3) The transfected CEF cells are planted on tissue culture plates and incubated until virus plaques become visible. (4) The identifiable plaques include recombinant virus as well as parent wild-type virus. The recombinant virus may be purified from wild type virus by any known method to detect expression of inserted foreign genes.
    • (Avian Influenza-Marek's Disease Bivalent Vaccine)
  • Since the HA protein is a protective antigen of avian influenza virus and the backbone HVT is a live Marek's disease vaccine, the recombinant HVT containing the HA gene in the present invention may be used as a bivalent vaccine against AI and Marek's disease or as a monovalent vaccine against AI.
  • The vaccine, consisting mainly of the recombinant HVT in the present invention, may also include avian cells, ingredients of culture media, buffers such as a phosphate buffer and HEPES buffer, and/or adjuvants such as cytokines and CpG oligodeoxynucleotide. As long as not pharmacologically detrimental, the vaccine may contain any ingredients such as preservatives. In addition, the vaccine of the present invention can be used in a mixture with any recombinant or non-recombinant viruses such as the MDV serotype I or serotype 2 vaccine strains.
  • Any known method is applicable to the preparation of the recombinant bivalent vaccine in the present invention. For instance, the recombinant HVT may be inoculated into permissive culture cells such as CEF cells and grown to an appropriate titer. Then, the cells are removed from tissue culture plates or roller bottles with cell scrapers or by trypsin treatment and collected by centrifugation. The pelleted cells are then suspended in culture medium containing dimethyl sulfoxide, frozen slowly, and then stored in liquid nitrogen. Alternatively, the recombinant HVT may be released from the infected cells by disrupting the cells in diluents containing stabilizers such as sucrose and bovine albumin. These released HVT is called cell-free HVT. Cell-free HVT may be lyophilized and stored at 4° C.
  • The bivalent recombinant HVT vaccine can be administered to chickens by any known method of inoculating Marek's disease vaccine. For instance, the vaccine of the present invention is diluted to give 101-105, or more favorably 102-104 plaque forming units (pfu) per dose with a diluent containing buffer components, sugars, and dye. The diluted vaccine may be inoculated subcutaneously behind the neck of one-day-old chicks or into embryonating eggs via the in ovo route with syringes or with any apparatus for injection.
  • The present avian bivalent vaccine is able to confer serological titer by HI of more than 50 (geometric mean titer) in groups of vaccinated chickens by 5 weeks post inoculation, when using four hemagglutination units of an inactivated avian influenza virus homologous H5 subtype antigen for the HI tests.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 Construction of the plasmid pGICMVpA
  • FIG. 2 Construction of the homology plasmid p45CMVH5Wis68
  • FIG. 3 Construction of the plasmid pGIBacpA2nd
  • FIG. 4 Construction of the homology plasmid p45BacH5Wis68
  • FIG. 5 Construction of the homology plasmid p45PecH5Wis68
  • FIG. 6 Western blot assay detecting expression of the hemagglutinin protein by the recombinant turkey herpesvirus
  • FIG. 7 Hemagglutination inhibition titers in chickens vaccinated with the recombinant turkey herpesvirus with hemagglutinin gene
  • FIG. 8 ELISA titers in chickens vaccinated with the recombinant turkey herpesvirus with hemagglutinin gene using a commercial ELISA kit (IDEXX LABORATORIES, FLOCKCHEK AIV)
  • FIG. 9 ELISA titers in chickens vaccinated with the recombinant turkey herpesvirus with hemagglutinin gene using a commercial ELISA kit (SYNBIOTICS, PROFLOK AIV Ab test kit)
    •  DETAILED DESCRIPTION OF THE INVENTION
  • Gene cloning and plasmid construction was essentially performed by the standard molecular biology techniques (Molecular Cloning: A Laboratory Manual. 3rd Edition, Cold Spring Harbor Laboratory Press, Woodbury, N.Y. 2001). The turkey herpesvirus FC126 strain (R. L. Witter et al., 1970, Am. J. Vet. Res. 31, 525-538) was used as a backbone virus to generate a recombinant turkey herpesvirus.
    • EXAMPLE 1 Hemagglutinin Gene Isolation from Avian Influenza Virus H5 Subtype
  • The avian influenza virus A/Turkey/Wisconsin/68 (H5N9) strain was propagated in the allantoic sac of specific pathogen free embryonating chicken eggs. Total genomic RNA from the A/Turkey/Wisconsin/68 virus was extracted using RNEASY MINI KIT (QIAGEN, Cat# 74104). First-strand cDNA was synthesized with SUPERSCRIPT FIRST-STRAND System for RT-PCR (Invitrogen, Cat# 11904-018). Using the resulting cDNA as a template, the HA gene was amplified by polymerase chain reaction (PCR) with PFUULTRA HIGH FIDELITY DNA Polymerase (STRATAGENE, Cat# 600380) and PCR primers. These PCR primers, BamHA-F primer (SEQ ID NO: 4) and SalHA-R primer (SEQ ID NO: 5), anneal to the start and stop sequences of the HA gene and each primer contains a sequence at the 5′ ends for a restriction enzyme, BamHI or SalI, respectively. After the PCR reaction, Taq polymerase (PROMEGA, Cat# M2665) was added to the PCR mixture to add 3′ A-overhangs to the PCR products.
  • BamHA-F primer (SEQ ID NO: 4)
    5′-TGACGGATCCATGGAAAGAATAGTGATTG-3′
    SalHA-R primer (SEQ ID NO: 5)
    5′-CTGACAGTCGACCTAGATGCAAATTCTGC-3′
  • The amplified 1.8 kilobase (kb) HA cDNA was inserted into PCR2.1-TOPO vector (INVITROGEN, Cat# K4500-01), resulting in pCR2.1-H5Wis68. Nucleotide sequences of the HA genes in a few clones of the plasmid pCR2.1-H5Wis68 and the PCR product were determined using ABI PRISM 3730XL DNA Analyzer (APPLIED BIOSYSTEMS) with six primers; BamHA-F primer (SEQ ID NO: 4), SalHA-R primer (SEQ ID NO: 5), M13 Forward primer (SEQ ID NO: 6), M13 Reverse primer (SEQ ID NO: 7), HA-F primer (SEQ ID NO: 8), and HA-R primer (SEQ ID NO: 9).
  • M13 Forward primer (SEQ ID NO: 6)
    5′-GTAAAACGACGGCCAGT-3′
    M13 Reverse primer (SEQ ID NO: 7)
    5′-GGAAACAGCTATGACCATG-3′
    HA-F primer (SEQ ID NO: 8)
    5′-CTGGACAATACTAAGGCCGAACGAT-3′
    HA-R primer (SEQ ID NO: 9)
    5′-CACTGGGGTCTGACATTTGGTA-3′
  • The sequences in the clones of the plasmid pCR2.1-H5Wis68 were identical to each other and to the sequence of the PCR product. Although the deduced amino acid sequence was different from the reported sequence of A/Turkey/Wisconsin/68 (H5N9) (M. Garcia et al., 1997, Virus Res. 51: 115-124, GenBank Accession# U79456) by four amino acids, the amino acids we obtained were the same as the amino acids of a majority of H5 subtype HA proteins. The nucleotide sequence and the deduced amino acid sequence of the HA gene obtained from A/Turkey/Wisconsin/68 (H5N9) are shown in SEQ ID NO: 1 and SEQ ID NO: 2.
    • EXAMPLE 2 Construction of Homology Plasmids 2-1. A Summary of Homology Plasmids and Recombinant Turkey Herpesviruses
  • In the present invention, three promoters, the CMV promoter, the chicken beta-actin promoter (Bac promoter), and a modified chicken beta-actin promoter (Pec promoter), were used to control expression of the HA gene of the AI virus A/Turkey/Wisconsin/68 (H5N9) strain. First, homology plasmids with the HA gene and one of the promoters were constructed and then recombinant turkey herpesviruses were generated using the homology plasmids. The recombinant turkey herpesviruses with different promoters were compared for capabilities of conferring serological titers against AI in chickens as shown in EXAMPLE 6. A recombinant HVT with the CMV promoter is presented here as an example and recombinant viruses with the Bac promoter or the Pec promoter are presented here as comparative examples. A list of the homology plasmids and the recombinant turkey herpesviruses constructed in the present invention is shown in TABLE 1.
  • TABLE 1
    A list of homology plasmids and recombinant turkey herpesviruses
    Name of Examples vs.
    Name of homology recombinant comparative
    Item # plasmids viruses Promoters examples
    1 p45CMVH5Wis68 rHVT/ CMV Example
    CMVH5Wis68 promoter
    2 p45BacH5Wis68 rHVT/ Bac Comparative
    BacH5Wis68 promoter example
    3 p45PecH5Wis68 rHVT/ Pec Comparative
    PecH5Wis68 promoter example

    2-2. Construction of Plasmid pGICMVpA
  • The CMV promoter was obtained from pBK-CMV (STRATAGENE, Cat. #212209). Three BglI restriction enzyme sites in the CMV promoter were disrupted for ease of the plasmid construction process by PCR in vitro mutagenesis using four pairs of primers. The primer pairs were PrCMV1 (SEQ ID NO: 10) and PrCMV3 (SEQ ID NO: 12), PrCMV4 (SEQ ID NO: 13) and PrCMV5 (SEQ ID NO: 14), PrCMV6 (SEQ ID NO: 15) and PrCMV2′ (SEQ ID NO: 11), and PrCMVo1 (SEQ ID NO: 16) and PrCMVR1 (SEQ ID NO: 17). Four PCR reactions were conducted separately using each pair of primers and pBK-CMV as a template. Then four PCR products were combined and used as a template for the secondary PCR with primers PrCMV1 and PrCMVR1, yielding the 604 bp fragment with a modified CMV promoter sequence. The nucleotide sequence of the CMV promoter used to express HA gene is provided in SEQ ID. NO. 3. The CMV promoter fragment was digested with PstI and XbaI and inserted into PstI and XbaI digested pUC18polyASfi (U.S. Pat. No. 6,866,852), resulting in pGICMV(−). The SV40 polyA signal was obtained from pBK-CMV by PCR using primers PolyA-SalKpn (SEQ ID NO: 18) and PolyA-SfiF2 (SEQ ID NO: 19). The PCR fragment containing SV40 polyA signal was digested with SalI and SfiI and ligated to pGICMV(−) digested with SalI and SfiI resulting in pGICMVpA (FIG. 1).
  • PrCMV1 (SEQ ID NO: 10)
    5′-GGGCTGCAGAGTTATTAATAGTAATCAATT-3′
    PrCMV2′ (SEQ ID NO: 11)
    5′-CGCGCCATTTACCGTCATTGACGTC-3′
    PrCMV3 (SEQ ID NO: 12)
    5′-GGGTCGTTGGGCGGTCAGCCGGCGG-3′
    PrCMV4 (SEQ ID NO: 13)
    5′-CTTACGGTAAATGGCCCGCCGGCTG-3′
    PrCMV5 (SEQ ID NO: 14)
    5′-TACACTTGATGTACTGCCAATGGGC-3′
    PrCMV6 (SEQ ID NO: 15)
    5′-TATTTACGGTAAACTGCCCATTGGC-3′
    PrCMVo1 (SEQ ID NO: 16)
    5′-ACGTCAATGACGGTAAATGGCGCGCCTGGC-3′
    PrCMVR1 (SEQ ID NO: 17)
    5′-CGTCTAGAGGATCTGACGGTTCACTAAACC-3′
    PolyA-SalKpn (SEQ ID NO: 18)
    5′-TGTGGTACCGTCGACGATTCACAGTCCCAAGGC-3′
    PolyA-SfiF2 (SEQ ID NO: 19)
    5′-CTTGGCCTTATTGGCCTAAGATACATTGATGAG-3′

    2-3. Construction of Homology Plasmid p45CMVH5Wis68
  • The CMV promoter and the SV40 polyA signal (940 bp) were excised from pGICMVpA by BglI and ligated into SfiI digested p45/46Sfi (U.S. Pat. No. 6,866,852), resulting in p45/46CMVpA. Then, the HA gene from A/Turkey/Wisconsin/68 (H5N9) was excised from pCR2.1-H5Wis68 using SalI and BamHI. The 1701 bp HA gene was inserted into p45/46CMVpA digested with SalI and BamHI, resulting in p45CMVH5Wis68 (FIG. 2). The plasmid p45CMVH5Wis68 was used as a homology plasmid to generate recombinant turkey herpesvirus.
  • 2-4. Construction of Plasmid pGIBacpA2nd
  • The Bac promoter was obtained by PCR using cellular DNA of CEF cells as a template. PrBac1 (SEQ ID NO: 18) and PrBac2′ (SEQ ID NO: 19) were the primer set used for PCR. An obtained 1.5-kilobase DNA fragment was digested with PstI and XbaI and inserted into PstI and XbaI digested pUC18polyASfi, resulting in pGIBac2. Then, the SV40 polyA signal obtained PCR using primers PolyA-SalKpn (SEQ ID NO: 18) and PolyA-SfiF2 (SEQ ID NO: 19) was digested with SalI and SfiI and ligated to pGIBac2 digested with SalI and SfiI resulting in pGIBacpA2nd (FIG. 3).
  • PrBac1 (SEQ ID NO: 20)
    5′-CAGTGTCGCTGCAGCTCAGTGCATGCACGCTCATTGCCC-3′
    PrBac2′ (SEQ ID NO: 21) 5′-
    GCTCTAGAGGCGTGGAGCTTGGGGGCTGCGGAGGAACAGAGAAGGGAAG-
    3′

    2-5. Construction of Homology Plasmid p45BaCH5Wis68
  • The Bac promoter and the SV40 polyA signal (1866 bp) were excised from pGIBacpA2nd by BglI and ligated into SfiI digested p45/46Sfi, resulting in p45/46BacpA2nd. Then, the HA gene of A/Turkey/Wisconsin/68 (H5N9) excised from pCR2.1-H5Wis68 using SalI and BamHI was inserted into p45/46BacpA2nd digested with SalI and BamHI, resulting in p45BaCH5Wis68 (FIG. 4).
  • 2-6. Construction of Homology Plasmid p45PeCH5Wis68
  • Construction of the Pec promoter is described in U.S. Pat. No. 6,866,852. The Pec promoter was synthesized by fusing a part of the chicken beta-actin promoter with the enhancer region of the CMV promoter. The Pec promoter was excise from pGIPec (U.S. Pat. No. 6,866,852) with PstI and BamHI and inserted into PstI and BamHI digested p45/46BacpA2nd described in EXAMPLE 2-4, resulting in p45/46PecpA2nd. Then, the HA gene of A/Turkey/Wisconsin/68 (H5N9) excised from pCR2.1-H5Wis68 using SalI and BamHI was inserted into p45/46PecpA2nd digested with SalI and BamHI, resulting in p45PeCH5Wis68 (FIG. 5).
    • EXAMPLE 3 Generation and Isolation of Recombinant Turkey Herpesvirus
  • Viral DNA of the HVT FC126 strain was prepared as described by Morgan et al. (Avian Diseases, 1990, 34:345-351).
  • 107 secondary chicken embryo fibroblast (CEF) cells were suspended in Saline G (0.14 M NaCl, 0.5 mM KCl, 1.1 mM Na2HPO4, 1.5 mM NaH2PO4, 0.5 mM MgCl2, and 0.011% glucose) and co-transfected with HVT viral DNA and 5 to 25 μg of the homology plasmid, p45CMVH5Wis68, p45BaCH5Wis68, or p45PeCH5Wis68 by electroporation. Electroporation was performed using BIO-RAD GENE PULSER. Transfected cells were incubated for 10 minutes at room temperature and transferred to wells of 96-well plates. After incubating at 37° C. for 7 days in 4-5% CO2, or until the plaques became visible, the cells were detached from the plates by trypsinization, transferred equally to two 96-well plates with secondary CEF and incubated for 3 to 4 days until plaques were observed. Screening was conducted by the black plaque assay, staining only plaques expressing HA protein. Briefly, one of the two plates was fixed with methanol:acetone mixture (1:2) and incubated with chicken anti-HA antiserum. Next, incubated with biotinylated anti-chicken IgG antibody (VECTOR LABORATORIES, Cat# BA-9010) and then with VECTASTAIN ABC-AP kit (Vector Laboratories, Cat# AK-5000), plaques expressing HA protein were stained by addition of BCIP/NBT solution (BIO-RAD LABORATORIES, Cat# 170-6539 and 170-6532). Wells containing stained recombinant plaques were identified and cells from the corresponding wells on the other 96-well plate were trypsinized. The cells were then diluted in fresh secondary CEF cells and transferred to 96-well plates to complete the first round of purification.
  • The purification procedure was repeated until all plaques were stained positively in the black plaque assay. Purified recombinant virus with the HA gene under the CMV promoter was designated as rHVT/CMVH5Wis68 (the present invention). Recombinant viruses with the Bac promoter or the Pec promoter were designated as rHVT/BaCH5Wis68 and rHVT/PeCH5Wis68, respectively (comparative examples).
    • EXAMPLE 4 Verification of Genome Structure and Stability of Recombinant HVT 4-1. Southern Blot Analysis
  • Chicken embryo fibroblast cells in a 100-mm dish that were infected with the recombinant virus, rHVT/CMVH5Wis68 or the HVT FC126 parent strain were used in the Southern blot analysis to confirm the insertion of the HA gene in the desired insertion site. The cells were collected by a cell scraper and by centrifugation at 913×g for 5 minutes. The harvested cells were washed with phosphate buffered saline (PBS) and resuspended in 1.0 milliliter (ml) of lysis buffer (0.5% TRITON X-100, 100 mM 2-mercaptethanol, and 20 mM EDTA in PBS). The cell suspension was vortexed for a total of 30 seconds and incubated for 15 minutes at room temperature. Cell nucleus and cell debris were removed by centrifuging at 2,060×g for 5 minutes and the supernatant was transferred to a 1.5-ml tube. Viruses were collected by centrifugation at 20,800×g for 20 minutes at 4° C. The pellet was suspended in 0.33 ml of a nuclease solution (12.5 mM Tris-Cl (pH7.5), 1 μg/ml DNase I and 1 μg/ml RNase A) and incubated at 37° C. for 30 minutes. Then, 83 μl of SDS-protease solution (50 mM EDTA, 5% SDS, 0.5 mg/ml protease K, and 25 mM 2-mercaptoethanol) was added to the virus suspension and incubated at 55° C. for 30 minutes to disrupt virus envelopes. Phenol chloroform extraction was conducted twice and DNA was precipitated by adding 2.5 volume of cold 100% ethanol and NaCl at a final concentration of 0.16 M. After centrifuging at 20,800×g for 30 minutes at 4° C., the pellet washed with 70% ethanol and air-dried. The pellet was dissolved in TE buffer (10 mM Tris-Cl (pH8.0), and 1 mM EDTA).
  • The viral DNA in TE buffer and the homology plasmid (positive control) were digested with XhoI, BamHI and SpeI and separated by agarose gel electrophoresis using 0.6% agarose gel. DNA fragments on the gel were transferred to a BIODYNE A nylon membrane (PALL, Cat# BNXF3R). The membrane was hybridized with either Digoxigenin (DIG)-labeled HA probe or DIG-labeled IS45/46 probe. The DIG-labeled HA probe and the IS45/46 probe were prepared with PCR DIG Probe Synthesis Kit (ROCHE APPLIED SCIENCE, Cat# 11636090910) using primers HA1-P-F (SEQ ID NO: 22) and HA1-P-R (SEQ ID NO: 23) and primers 45/46-F (SEQ ID NO: 24) and 45/46-R (SEQ ID NO: 25), respectively.
  • HA1-P-F (SEQ ID NO: 22)
    5′-GGGGGTGGCAAGGAATG-3′
    HA1-P-R (SEQ ID NO: 23)
    5′-GCTAGGGAACTCGCCACTGT-3′
    45/46-F-B (SEQ ID NO: 24)
    5′-TAGCGGCACGGAAACAGATAGAGA-3′
    45/46-R-B (SEQ ID NO: 25)
    5′-TGGCGATACGGTTCCTGGTTTGAC-3′
  • The membrane washed with 2×SSC solution at room temperature and then with 0.5×SSC solution at 68° C. The membrane was blocked and incubated with anti-Digoxigenin-AP, Fab fragments (ROCHE APPLIED SCIENCE, Cat# 11093274910) for 30 minutes at room temperature. After washing two times with maleic acid washing buffer (0.1 M maleic acid, 0.15 M NaCl, and 0.3% Tween20, pH 7.5), DNA bands that were hybridized with the probes were visualized by incubating the membrane with BCIP/NBT solution. The HA probe hybridized with 3.6 kb bands in the recombinant virus DNA and the homology plasmid, while no bands were detected with the HVT parent. The IS45/46 probe hybridized with 3.6 kb and 1.2 kb bands in the recombinant DNA and the homology plasmid, and with 2.3 kb band in the HVT parent. These results demonstrated that rHVT/CMVH5Wis68 obtained in EXAMPLE 3 had an expected genomic structure.
  • Southern blot analysis of rHVT/BaCH5Wis68 and rHVT/PeCH5Wis68 was conducted in a similar way as that of rHVT/CMVH5Wis68, except that XhoI and SpeI restriction enzymes were used for rHVT/BaCH5Wis68. For rHVT/BaCH5Wis68, the HA probe hybridized with 4.9 kb bands in the recombinant virus DNA and the homology plasmid, while no bands were detected with the HVT parent. The IS45/46 probe hybridized with 4.9 kb and 0.8 kb bands in the recombinant DNA and the homology plasmid, and with 2.3 kb band in the HVT parent. For rHVT/PeCH5Wis68, the HA probe hybridized with 3.6 kb bands in the recombinant virus DNA and the homology plasmid, while no bands were detected with the HVT parent. The IS45/46 probe hybridized with 3.6 kb and 1.2 kb bands in the recombinant DNA and the homology plasmid, and with 2.3 kb band in the HVT parent. These recombinant viruses were also demonstrated to have expected genomic structures.
    • 4.2. Stability of Recombinant HVT
  • The recombinant viruses, rHVT/CMVH5Wis68, rHVT/BaCH5Wis68, and rHVT/PeCH5Wis68, were passed 20 times blindly in CEF cells. After the 20 passages, the viruses were analyzed by the Southern blot analysis as described in EXAMPLE 4.1. Bands detected in DNA isolated from the virus after 20 passages were identical to the bands described in EXAMPLE 4.1, demonstrating that the recombinant viruses were stable even after 20 passages.
    • EXAMPLE 5 HA Protein Expression by Recombinant HVT
  • Expression of the HA protein by the recombinant viruses, rHVT/CMVH5Wis68, rHVT/BaCH5Wis68, and rHVT/PeCH5Wis68, was confirmed by the black plaque assay and the Western blot assay. Procedures for the black plaque assay are described in EXAMPLE 3. The western blot was conducted using CEF cells infected with the recombinant viruses and chicken anti-HA antiserum. Briefly, CEF cells in 100-mm dishes were infected with one of the recombinant viruses or the parent HVT FC126 strain at a multiplicity of infection of approximately 0.01. Two to three days post inoculation, cells were harvested with cell scrapers and centrifuged at 913×g for 5 minutes. The pellet washed with PBS twice and resuspended with 50 to 100 μl of PBS. After adding the same volume of 2×SDS sample buffer (130 mM Tris-Cl (pH6.8), 6% SDS, 20% Glycerol, 10% 2-Mercaptoethanol and 0.01% Bromo Phenol Blue), cell suspension was boiled for 5 minutes. The samples were separated by SDS-PAGE using 8% polyacrylamide gel and transferred to a PVDF membrane (IMMOBILON-P, MILLIPORE). The membrane was dried completely and then incubated with chicken anti-HA antiserum. After the anti-HA antiserum washed off, the membrane was incubated with alkaline phosphatase-conjugated anti-chicken IgG Fc antibody (BETHYL, Cat# A30-104AP). Protein bound with chicken anti-HA antiserum was visualized by adding BCIP/NBT solution. As shown in FIG. 3, a protein band of 74 kilodaltons (kDa) was observed only in the lane with the recombinant virus infected cells, which was the expected size of the non-processed HA protein.
    • EXAMPLE 6 Serological Evaluation of Chickens Inoculated with Recombinant HVT
  • Serological responses against AI in chickens that were vaccinated with the recombinant viruses, rHVT/CMVH5Wis68, rHVT/PeCH5Wis68, and rHVT/BaCH5Wis68, were evaluated. One-day-old specific pathogen free chicks (SPAFAS, Flock T-10) were vaccinated subcutaneously with one of the recombinant viruses. Groups 1 and 2 were inoculated with 1638 pfu per dose (0.2 ml) and 375 pfu per dose of rHVT/CMVH5Wis68, respectively (TABLE 2). Groups 3 and 4 contained chickens vaccinated with 2800 pfu (Group 3) or 550 pfu (Group 4) of rHVT/PeCH5Wis68. Groups 5 and 6 were inoculated with 4350 pfu and 720 pfu per dose of rHVT/BacH5Wis68, respectively. A group of chickens (Group 8) were held as non-inoculated negative controls. Another group of chickens (Group 7) was vaccinated subcutaneously with inactivated A/Turkey/Wisconsin/68 (H5N9) vaccine at three weeks old as an inactivated vaccine control. Chickens were bled between 3 to 7 weeks old and obtained sera were evaluated by the AI HI tests and AIV ELISA tests. The AI HI tests were conducted using four hemagglutination units of an inactivated avian influenza virus homologous antigen of the A/Turkey/Wisconsin/68 (H5N9) strain, the HA gene of which was used in the recombinant viruses, as described by D. E. Swayne et al. (D. E. Swayne et al., 1998, Avian Influenza. In: A Laboratory Manual for the Isolation and Identification of Avian Pathogens, 150-155). Briefly, before the HI assay, the number of the hemagglutination units in the inactivated A/Turkey/Wisconsin/68 (H5N9) antigen was determined as the highest dilution of the antigen giving complete agglutination, and the antigen was diluted to contain four hemagglutination units in 25 μl. In U-bottom 96 well plates, the sera were initially diluted 1:5 and then serially diluted by two fold across the plates with phosphate buffered saline (PBS) to contain 25 μl per well. Four hemagglutination units of the antigen in 25 μl were added to each well and incubated for 30 minutes at room temperature. Finally, 50 μl of 0.5% chicken erythrocytes in PBS was added to each well and incubated for about 40 minutes at room temperature. HI titers are the highest dilution of the sera exhibiting inhibition of hemagglutination. HI titers of equal to or more than 10 were considered positive. The ELISA tests were conducted using two commercial AIV ELISA kits (IDEXX Laboratories, FLOCKCHEK AIV and SYNBIOTICS, PROFLOK AIV Ab test kit) that are available in the United States.
  • As shown in TABLE 3 and FIG. 7, sera from chickens vaccinated with rHVT/CMVH5Wis68 (Groups 1 and 2) started to show HI titers as early as three weeks post vaccination and the HI titers continued to increase up to the HI titer of 100 (geometric mean titer) by six weeks post vaccination. Also, more than 80% of vaccinated chickens at three weeks post vaccination and all vaccinated chickens after five weeks post vaccination had HI titers of equal to or more than 10 (TABLE 3). High levels of HI titers have not been consistently observed with the commercial fowlpox-vectored AIV vaccine and this was not easily accomplished. The dose difference between two vaccine groups (1638 pfu and 375 pfu) did not have a significant influence on serological responses. Surprisingly, when tested with the commercial AIV ELISA kits, these sera from rHVT/CMVH5Wis68-vaccinated chickens that were highly positive by the HI tests did not give positive ELISA titers through 3 and 7 weeks post vaccination, whereas sera collected from the inactivated vaccine control (Group 7) showed highly positive ELISA titers with both commercial ELISA kits (FIGS. 8 and 9). This feature of the rHVT/CMVH5Wis68 vaccine would make it extremely easy to differentiate vaccine reactions from field virus exposure and to track vaccinated chickens. Geometric mean HI titers of sera from chickens vaccinated with rHVT/PecH5Wis68 (Groups 3 and 4) or rHVT/BacH5wis68 (Groups 5 and 6) were not as high as those conferred by rHVT/CMVH5Wis68. Also, rHVT/PeCH5Wis68 and rHVT/BacH5Wis68 failed to confer serological titer by HI to vaccinated chickens consistently as shown in TABLE 3. The non-inoculated negative controls (Group 8) did not show positive serological results in either the HI tests or the ELISA tests throughout the observation period.
  • In summary, the recombinant HVT with the HA gene in combination with the CMV promoter (rHVT/CMVH5wis68) provided vaccinated chickens with higher and more uniform serology titers by HI than the recombinant HVT with the Bac promoter (rHVT/BacH5Wis68) and the recombinant HVT with the Pec promoter (rHVT/PecH5Wis68), which are presented here as comparative examples. The sera collected from chickens vaccinated from rHVT/CMVH5Wis68 were negative by commercially available AIV ELISA kits although the sera were highly positive by the AI HI tests, thus enabling easy differentiation between reaction from vaccination and field infection.
  • TABLE 2
    Treatment groups
    Age of Vaccine Vaccine # of
    Group # Treatment Group Promoters vaccination dose (pfu1) route chickens
    1 rHVT/CMVH5Wis68 CMV (Ex2) One-day-old 1638 SQ3 17
    2 rHVT/CMVH5Wis68 CMV (Ex) One-day-old 375 SQ 17
    3 rHVT/PecH5Wis68 Pec (CE4) One-day-old 2800 SQ 17
    4 rHVT/PecH5Wis68 Pec (CE) One-day-old 550 SQ 17
    5 rHVT/BacH5Wis68 Bac (CE) One-day-old 4350 SQ 17
    6 rHVT/BacH5Wis68 Bac (CE) One-day-old 720 SQ 17
    7 Inactivated H5N9 vaccine N/A5 3-weeks-old 0.5 ml6 SQ 17
    8 Negative controls N/A N/A None N/A 10
    pfu1 = plaque forming units
    Ex2 = example
    SQ3 = subcutaneous
    CE4 = comparative example
    N/A5 = not applicable
    ml6 = milliliter
  • TABLE 3
    HI titers
    3 weeks 4 weeks 5 weeks 6 weeks 7 weeks
    Group Positive1/ GMT Positive/ GMT Positive/ GMT Positive/ GMT Positive/ GMT
    # Total titer2 Total titer Total titer Total titer Total titer
    1 16/17 23.5 15/17 47.1 17/17 62.6 17/17 94.2 17/17 70.8
    (94%) (88%) (100%)  (100%)  (100%) 
    2 14/17 18.4 17/17 47.1 17/17 53.2 16/16 113.1 16/16 118.1
    (82%) (100%)  (100%)  (100%)  (100%) 
    3 15/17 17.7 16/17 24.5 16/17 28.9 17/17 38.4 16/17 47.1
    (88%) (94%) (94%) (100%)  (94%)
    4 14/17 23.5 16/17 28.9 15/17 23.5 13/17 23.2 14/17 28.9
    (82%) (94%) (88%) (76%) (82%)
    5 16/17 35.4 16/17 32.6 15/17 25.5 14/17 21.4 13/17 28.5
    (94%) (94%) (88%) (82%) (76%)
    6 11/17 11.0 11/17 11.6 12/17 9.5 10/17 13.9 10/16 10.9
    (65%) (65%) (71%) (59%) (63%)
    7 N/A3 N/A N/A N/A N/A N/A 17/17 294.9 17/17 461.9
    (100%)  (100%) 
    8  0/10 N/A  0/10 N/A  0/10 N/A  0/10 N/A  0/10 N/A
     (0%)  (0%)  (0%)  (0%)  (0%)
    Positive1 = HI titers of equal to or more than 10 were considered positive.
    GMT titer2 = Geometric mean titer
    N/A3 = not applicable

Claims (10)

1. A recombinant turkey herpesvirus comprising a hemagglutinin gene of avian influenza virus and the cytomegalovirus immediate early promoter, wherein said hemagglutinin gene is under control of said promoter.
2. A recombinant turkey herpesvirus as in claim 1, wherein said hemagglutinin gene and said promoter are present in a non-essential region of the turkey herpesvirus genome.
3. A recombinant turkey herpesvirus as in claim 2, wherein said non-essential region is between UL45 and UL46 of the turkey herpesvirus genome.
4. A recombinant turkey herpesvirus as in claim 1, wherein said avian influenza virus is H5 subtype.
5. A recombinant turkey herpesvirus as in claim 1, wherein said avian influenza virus is A/Turkey/Wisconsin/68 (H5N9) strain.
6. A recombinant turkey herpesvirus as in claim 1, wherein a nucleotide sequence of said hemagglutinin gene is shown in SEQ ID NO: 1.
7. A poultry vaccine comprising a recombinant turkey herpesvirus as in claim 1.
8. A poultry vaccine comprising a recombinant turkey herpesvirus as in claim 1 wherein said vaccine confers hemagglutination inhibition titers of more than 50 (geometric mean titer) by five weeks post vaccination in vaccinated chickens, wherein said hemagglutination inhibition titers are defined as the highest dilutions of sera exhibiting inhibition of hemagglutination when using four hemagglutination units of an inactivated avian influenza virus homologous antigen.
9. A method of conferring high hemagglutination inhibition titers by inoculating chickens with a recombinant turkey herpesvirus as in claim 1.
10. A method as in claim 9, wherein said inoculated chickens develop hemagglutination inhibition titers of more than 50 (geometric mean titer) by five weeks post vaccination, wherein said hemagglutination inhibition titers are defined as the highest dilutions of sera exhibiting inhibition of hemagglutination when using four hemagglutination units of an inactivated avian influenza virus homologous antigen.
US11/729,978 2007-03-30 2007-03-30 Turkey herpesvirus vectored recombinant containing avian influenza genes Abandoned US20080241188A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US11/729,978 US20080241188A1 (en) 2007-03-30 2007-03-30 Turkey herpesvirus vectored recombinant containing avian influenza genes
BRPI0809529-9A BRPI0809529B1 (en) 2007-03-30 2008-03-28 RECOMBINANT VECTORIZED TURKEY HERPESVIRUS COMPRISING AN AVIAN INFLUENZA VIRUS HEMAGLUTININ GENE AND VACCINE FOR POULTRY
PCT/US2008/004070 WO2008121329A2 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes
PL08727197T PL2129390T3 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes
EP08727197A EP2129390B1 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes
JP2010502098A JP5508252B2 (en) 2007-03-30 2008-03-28 Recombinant turkey herpesvirus containing avian influenza gene
ES08727197T ES2399845T3 (en) 2007-03-30 2008-03-28 Recombinant vector turkey herpesvirus containing avian influence genes
CN2008800166743A CN101903040A (en) 2007-03-30 2008-03-28 The turkey herpesvirus vectored recombinant that contains avian influenza genes
US12/449,037 US8927270B2 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes
US14/551,487 US10072272B2 (en) 2007-03-30 2014-11-24 Turkey herpesvirus vectored recombinant containing avian influenza genes
US16/114,265 US10655146B2 (en) 2007-03-30 2018-08-28 Turkey herpesvirus vectored recombinant containing avian influenza genes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/729,978 US20080241188A1 (en) 2007-03-30 2007-03-30 Turkey herpesvirus vectored recombinant containing avian influenza genes

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2008/004070 Continuation-In-Part WO2008121329A2 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes
US12/449,037 Continuation-In-Part US8927270B2 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes
US12/449,037 Continuation US8927270B2 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes
US44903709A Continuation-In-Part 2007-03-30 2009-07-21

Publications (1)

Publication Number Publication Date
US20080241188A1 true US20080241188A1 (en) 2008-10-02

Family

ID=39794757

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/729,978 Abandoned US20080241188A1 (en) 2007-03-30 2007-03-30 Turkey herpesvirus vectored recombinant containing avian influenza genes
US12/449,037 Active 2028-12-17 US8927270B2 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes
US14/551,487 Active US10072272B2 (en) 2007-03-30 2014-11-24 Turkey herpesvirus vectored recombinant containing avian influenza genes
US16/114,265 Active US10655146B2 (en) 2007-03-30 2018-08-28 Turkey herpesvirus vectored recombinant containing avian influenza genes

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/449,037 Active 2028-12-17 US8927270B2 (en) 2007-03-30 2008-03-28 Turkey herpesvirus vectored recombinant containing avian influenza genes
US14/551,487 Active US10072272B2 (en) 2007-03-30 2014-11-24 Turkey herpesvirus vectored recombinant containing avian influenza genes
US16/114,265 Active US10655146B2 (en) 2007-03-30 2018-08-28 Turkey herpesvirus vectored recombinant containing avian influenza genes

Country Status (7)

Country Link
US (4) US20080241188A1 (en)
EP (1) EP2129390B1 (en)
JP (1) JP5508252B2 (en)
CN (1) CN101903040A (en)
ES (1) ES2399845T3 (en)
PL (1) PL2129390T3 (en)
WO (1) WO2008121329A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119112A1 (en) 2009-04-15 2010-10-21 Ceva Sante Animale Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
US20110110887A1 (en) * 2008-06-23 2011-05-12 Wilhelmus Gerardus Johannes Degen Recombinant herpesvirus of turkeys encoding for interleukin-12
WO2012052384A1 (en) 2010-10-18 2012-04-26 Intervet International B.V. Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
CN109142734A (en) * 2018-10-26 2019-01-04 北京纳百生物科技有限公司 H_5 subtype Re-6 strain antibody identification kit
CN110205308A (en) * 2019-05-24 2019-09-06 华南农业大学 It is a kind of express HA gene recombinant herpesvirus of turkeys and its application

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140557A2 (en) 2006-10-24 2008-11-20 Samuel Bogoch A method of predicting influenza outbreaks
KR20100006574A (en) 2007-05-30 2010-01-19 사무엘 보고치 Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
EP2421546A1 (en) * 2009-04-23 2012-02-29 Samuel Bogoch Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
US9320784B2 (en) 2009-08-07 2016-04-26 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
EP2644702A1 (en) * 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
CN103740759B (en) * 2014-01-20 2016-04-06 中国农业科学院哈尔滨兽医研究所 Express the recombinant herpesvirus of turkeys of H5N1 HA Gene of H 9 Subtype AIV
US11596687B2 (en) 2016-06-17 2023-03-07 Intervet Inc. Recombinant non-pathogenic Marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
CN106497893A (en) * 2016-10-28 2017-03-15 扬州大学 The recombinant herpesvirus of turkeys strain rHMW and construction method of expression H7N9 subtype avian influenza virus mosaic type hemagglutinins
CN106399267A (en) * 2016-10-28 2017-02-15 扬州大学 Recombinant turkey herpesvirus virus strain rHOH expressing H7N9 subtype avian influenza virus haemagglutinin protein and construction method
WO2019072964A1 (en) 2017-10-12 2019-04-18 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding multiple heterologous antigens
CN109402071B (en) * 2018-11-08 2021-04-27 中国农业大学 Recombinant turkey herpesvirus expressing H9N2 subtype avian influenza virus H9 protein
CN116457461A (en) 2020-10-15 2023-07-18 法国诗华动物保健公司 Recombinant HVT and its use
CN114184797B (en) * 2021-12-06 2024-06-14 辽宁成大生物股份有限公司 Method for detecting influenza virus split vaccine monovalent stock solution hemagglutinin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632664B1 (en) * 1997-10-03 2003-10-14 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5853733A (en) * 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
US6410222B1 (en) * 1998-12-14 2002-06-25 Juridical Foundation The Chemosero-Therapeutic Research Institute In ovo vaccination of marek's disease type I virus
US6866852B2 (en) * 2002-01-31 2005-03-15 Zeon Corporation Recombinant herpesvirus of turkeys and use thereof
ZA200508930B (en) * 2003-05-05 2007-03-28 Thompson Boyce Inst Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
WO2007022151A2 (en) * 2005-08-15 2007-02-22 Vaxin, Inc. Immunization of avians by administration of non-replicating vectored vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632664B1 (en) * 1997-10-03 2003-10-14 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110110887A1 (en) * 2008-06-23 2011-05-12 Wilhelmus Gerardus Johannes Degen Recombinant herpesvirus of turkeys encoding for interleukin-12
WO2010119112A1 (en) 2009-04-15 2010-10-21 Ceva Sante Animale Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
WO2012052384A1 (en) 2010-10-18 2012-04-26 Intervet International B.V. Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
US20130230556A1 (en) * 2010-10-18 2013-09-05 Paulus Jacobus Antonius Sondermeijer Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
US8986987B2 (en) * 2010-10-18 2015-03-24 Intervet Inc. Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
CN109142734A (en) * 2018-10-26 2019-01-04 北京纳百生物科技有限公司 H_5 subtype Re-6 strain antibody identification kit
CN110205308A (en) * 2019-05-24 2019-09-06 华南农业大学 It is a kind of express HA gene recombinant herpesvirus of turkeys and its application

Also Published As

Publication number Publication date
JP5508252B2 (en) 2014-05-28
US20100092510A1 (en) 2010-04-15
US10655146B2 (en) 2020-05-19
BRPI0809529A2 (en) 2014-10-14
US10072272B2 (en) 2018-09-11
JP2010532157A (en) 2010-10-07
EP2129390A2 (en) 2009-12-09
PL2129390T3 (en) 2013-06-28
US8927270B2 (en) 2015-01-06
ES2399845T3 (en) 2013-04-03
EP2129390B1 (en) 2012-11-21
WO2008121329A3 (en) 2010-04-22
EP2129390A4 (en) 2010-09-22
CN101903040A (en) 2010-12-01
US20170298386A9 (en) 2017-10-19
US20150110835A1 (en) 2015-04-23
US20180363006A1 (en) 2018-12-20
WO2008121329A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
US10655146B2 (en) Turkey herpesvirus vectored recombinant containing avian influenza genes
JP6845266B2 (en) Vaccines for immunizing multivalent recombinant herpesviruses and birds
DK2785374T3 (en) RECOMBINANT GALLID HERPES VIRUS 3 (MDV SEROTYPE 2) VECTORS EXPRESSING ANTIGEN OF PATH CREATURES AND APPLICATIONS THEREOF
Li et al. Recombinant herpesvirus of turkeys as a vector-based vaccine against highly pathogenic H7N1 avian influenza and Marek's disease
Toro et al. Infectious bronchitis virus subpopulations in vaccinated chickens after challenge
RU2692013C2 (en) Improved nd-ibd vaccine based on hvt vector
Tian et al. Protection of chickens against hepatitis-hydropericardium syndrome and Newcastle disease with a recombinant Newcastle disease virus vaccine expressing the fowl adenovirus serotype 4 fiber-2 protein
CN110536697A (en) The 3 type avian herpetoviruses vaccine of recombination of encoding heterologous poultry pathogens antigen
JP6210998B2 (en) Infectious disease prevention method by combined use of vector vaccine and live vaccine
US6866852B2 (en) Recombinant herpesvirus of turkeys and use thereof
JP2023506919A (en) Multivalent HVT vector vaccine
CN102373180A (en) Recombinant duck enteritis virus (DEV) vaccine strain for expressing avian influenza virus haemagglutinin (HA) gene and constructing method and application thereof
US7569365B2 (en) Promoter gene, recombinant turkey herpesvirus having the novel promoter gene, and poultry vaccine including the recombinant herpes virus of turkey
US11696947B2 (en) H52 IBV vaccine with heterologous spike protein
CN102559610B (en) Recombined duck virus enteritis viral vaccine strain CCTCC for expressing bird flu virus hemagglutinin (HA) gene (rDEVus78Ha) as well as establishing method and application thereof
Williams et al. A recombinant bovine herpesvirus-4 vectored vaccine delivered via intranasal nebulization elicits viral neutralizing antibody titers in cattle
Choi et al. Preparation and diagnostic utility of a hemagglutination inhibition test antigen derived from the baculovirus-expressed hemagglutinin-neuraminidase protein gene of Newcastle disease virus
Wang et al. Identification of novel T-cell epitopes on viral protein VP4 of Infectious Bursal Disease Virus (IBDV) that play critical roles in eliciting cellular immune response
US20110311994A1 (en) Avian vaccines possessing a positive marker gene
WO2025044919A2 (en) New dev vectors
BRPI0809529B1 (en) RECOMBINANT VECTORIZED TURKEY HERPESVIRUS COMPRISING AN AVIAN INFLUENZA VIRUS HEMAGLUTININ GENE AND VACCINE FOR POULTRY
Choi KangSeuk et al. Preparation and diagnostic utility of a hemagglutination inhibition test antigen derived from the baculovirus-expressed hemagglutinin-neuraminidase protein gene of Newcastle disease virus.

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZEON CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ESAKI, MOTOYUKI;REEL/FRAME:019443/0363

Effective date: 20070514

Owner name: BIOMUNE COMPANY, KANSAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JENSEN, LAUREN ELIZABETH;DORSEY, KRISTI M.;REEL/FRAME:019443/0386

Effective date: 20070514

AS Assignment

Owner name: ZEON CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOMUNE CORPORATION;REEL/FRAME:019686/0049

Effective date: 20070531

AS Assignment

Owner name: ZEON CORPORATION, JAPAN

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME, PREVIOUSLY RECORDED AT REEL/FRAME 0196;ASSIGNOR:BIOMUNE COMPANY;REEL/FRAME:019880/0408

Effective date: 20070531

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载